Australian biotech market watch 17/11/09
Tuesday, 17 November, 2009
The All Ordinaries has retracted after seeing a surge in early trading. As of 2.45pm this afternoon it's down 18 points to 4,755 from a of 4,809 at 10am.
Xenotransplantation specialists, Living Cell Technologies (ASX:LCT), are up by 9.5% to 29c after its announcement of a share purchase plan yesterday. This means the price of 25c per share being offered by LCT is equivalent to a 15% discount from the current price.
Prima Biomed (ASX:PRR) issued a trading halt this morning pending an announcement of an oral vaccine for cervical cancer. It last traded at 16.5c, up 3.1%.
Mesoblast (ASX:MSB) also saw impressive gains this morning, up 8c to $1.36. Cancer drug company, ChemGenex, put on 3.7% to 98.5c.
Also experiencing rises were Sirtex (ASX:SRX), up 16c to $6.66, Ramsay Health Care (ASX:RHC), up 12c to $10.91 and Cellestis (ASX:CST), up 4c to $3.84.
Falls were seen by Blackmores (ASX:BKL), down 1.4% to $20.71, and Ansell (ASX:ANN), down a similar amount to $10.26.
The majors remained fairly steady.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
